Skip to main content


Acetate transiently inhibits myocardial contraction by increasing mitochondrial calcium uptake

Article metrics

  • 3428 Accesses

  • 1 Citations



There is a close relationship between cardiovascular disease and cardiac energy metabolism, and we have previously demonstrated that palmitate inhibits myocyte contraction by increasing Kv channel activity and decreasing the action potential duration. Glucose and long chain fatty acids are the major fuel sources supporting cardiac function; however, cardiac myocytes can utilize a variety of substrates for energy generation, and previous studies demonstrate the acetate is rapidly taken up and oxidized by the heart. In this study, we tested the effects of acetate on contractile function of isolated mouse ventricular myocytes.


Acute exposure of myocytes to 10 mM sodium acetate caused a marked, but transient, decrease in systolic sarcomere shortening (1.49 ± 0.20% vs. 5.58 ± 0.49% in control), accompanied by a significant increase in diastolic sarcomere length (1.81 ± 0.01 μm vs. 1.77 ± 0.01 μm in control), with a near linear dose response in the 1–10 mM range. Unlike palmitate, acetate caused no change in action potential duration; however, acetate markedly increased mitochondrial Ca2+ uptake. Moreover, pretreatment of cells with the mitochondrial Ca2+ uptake blocker, Ru-360 (10 μM), markedly suppressed the effect of acetate on contraction.


Lehninger and others have previously demonstrated that the anions of weak aliphatic acids such as acetate stimulate Ca2+ uptake in isolated mitochondria. Here we show that this effect of acetate appears to extend to isolated cardiac myocytes where it transiently modulates cell contraction.


It is well established that the cardiac myocardium is capable of oxidizing a variety of carbon sources to supply the energy required for continuous contraction. Lipids, carbohydrates, ketone bodies, and amino acids can all support some degree of ATP synthesis in the heart. The loss of metabolic flexibility in the diseased heart may lead to abnormal contractile function. For example, we recently demonstrated that mice overexpressing fatty acid transport protein (FATP4) in the heart have impaired diastolic function [1]. Similarly, acute exposure to long chain fatty acids has been shown to cause a decrease in cardiomyocyte contractility through effects on increases in voltage gated K+ currents thus causing shortening of the action potential [2].

In a continued effort to understand the relationship of cardiac metabolism and cell function, we set out to test the effects of acetate on contraction. Several studies have examined the effect of acetate on cardiac contraction with equivocal results. In isolated cells, acetate tends to increase cell shortening after 10 minutes of exposure [3]. In isolated papillary muscle and in vivo, sodium acetate has been shown to reduce contractility [4],[5], whereas other studies suggest that acetate causes an increase in contractility [6]. The effects of acetate on cardiovascular function in vivo are complicated by the concomitant vasodilatory effects that also must be considered [6]. These mixed results are consistent with the idea that acetate can affect cardiac contractility, but the cellular mechanisms remain poorly understood.

Although it is typically found in low concentrations (~0.2 mM) in non-ruminant mammals [7], acetate oxidation can account for ~10% of the total CO2 output in humans [8]. Acetate can be converted to acetyl CoA by acetyl CoA sythetase (AceCS2) in the mitochondrial matrix [9] and the resultant acetyl CoA can then enter the tricarboxylic acid (TCA) cycle. The heart is unique in that the expression of the mitochondrial AceCS2 is higher than in any other tissue, so the heart is ideally suited to use acetate as a fuel source [9]. Metabolic studies by Randle demonstrate that acetate is rapidly oxidized in the myocardium [10]. In some isolated heart studies, acetate combustion can account for ~90% of total respiration to the exclusion of glucose oxidation [11], although others suggest that at physiological workloads both acetate and glucose are effectively utilized [12]. Acetate can also affect isolated mitochondria independent of its oxidation, where Lehninger and others have demonstrated that exposure to acetate causes a rapid increase in mitochondrial matrix Ca2+ and osmotic swelling [13]-[15].

In this context, we investigated the effects of acetate on cardiac contractility in isolated cardiac myocytes. We tested the effects of acetate throughout a 10 minute exposure. The results demonstrate that acetate inhibits systolic function and increases cell relaxation within 2 minutes of exposure. The decrease in systolic function is transient, however, and contraction amplitude is restored within 10 minutes. These effects are independent of changes in action potential duration; however, the effects of acetate were inhibited by blockade of mitochondrial Ca2+ uptake with Ru-360, indicating that acetate causes effects on cardiac contraction by increasing Ca2+ uptake into the mitochondria.


Animal subjects

All animals used in this study were male, aged 2–4 months, C57Bl6/J. All procedures complied with the standards for the care and use of animal subjects as stated in the Guide for the Care and Use of Laboratory Animals (NIH publication No. 85–23, revised 1996). Protocols were approved by the USUHS Institutional Animal Care and Use Committee.

Solutions (concentrations in mM)

Normal Tyrode Soution (NT): NaCl, 137; KCl, 5.4; NaH2PO4, 0.16; glucose, 10; MgCl2, 0.5; CaCl2, 1.8; HEPES, 5.0; NaHCO3, 3.0; pH 7.35 - 7.4.

Wittenberg Isolation Medium (WIM): NaCl, 116; KCl, 5.3; NaH2PO4, 1.2; glucose, 11.6; MgCl2, 3.7; HEPES, 20; L-glutamine, 2.0; NaHCO3, 4.4; KH2PO4, 1.5; 1X essential vitamins; 1X amino acids; pH 7.3-7.4.

Myocyte isolation

Isolation of ventricular myocytes was performed as described previously [1],[2],[16]. Briefly, mice were anesthetized by intra-peritoneal injection with 2,2,2 tribromoethanol (250 mg/kg). Following cervical dislocation, the heart was rapidly excised and the aorta cannulated. The heart was retrogradely perfused with Ca2+-free WIM solution for 5 minutes followed by perfusion with a digestion solution containing 100 μM CaCl2 and 1 mg/mL collagenase (Type 2, Worthington Biochemical). Left ventricular cells were gently dispersed by manual trituration using a pasteur pipette in WIM solution supplemented with bovine serum albumin (1 mg/mL) and 500 μM CaCl2. Cells were washed twice with WIM solution and twice with HEPES-buffered M199 solution and stored at room temperature. Cells were used for experiments within 12 hours of isolation in all cases.

Myocyte contraction measurements

Unloaded sarcomere shortening was measured in freshly isolated ventricular myocytes, as described previously [1],[2]. Briefly, isolated myocytes were transferred into a recording chamber mounted on an Olympus X51 inverted microscope and superfused with normal Tyrode solution saturated with room air. Additions to the Tyrode solution are described in the text. The mitochondrial calcium uptake inhibitor, Ru-360, was obtained from EMD Biosciences; all other chemicals were purchased from Sigma. Typically, cells were field stimulated to contract at 1 Hz. When thapsigargin was applied to cells, the stimulation frequency was reduced to 0.5 Hz. Video images were acquired using a Myocam camera and IonWizard software (IonOptix, Inc.). All experiments were performed at room temperature.

Mitochondrial Ca2+ measurements

Freshly isolated ventricular myocytes were plated on laminin-coated (100 μg/mL) Mat-Tek dishes for fluorescence imaging. Cells were loaded with Rhod-2-AM (5 μM) for 30 minutes in normal Tyrode solution containing probenecid (500 μM) to inhibit dye export and 200 μM MnCl2 to quench cytoplasmic fluorescence as has been previously reported [17],[18]. After loading, cells were washed twice with normal Tyrode solution supplemented with probenecid and 200 μM MnCl2 and transferred to the microscope stage. Cell images were obtained every 10 seconds for 10 minutes. Data were plotted as background-subtracted Rhod-2-AM fluorescence normalized to mean signal during the first 6 images recorded prior to addition of acetate.

Action potential measurements

Action potentials were measured in freshly isolated ventricular myocytes using whole cell current clamp. Briefly, following acquisition of the whole cell mode, cell holding potential was adjusted to −70 mV using current injection. Action potentials were evoked by suprathreshold stimuli (2 nA, 3 msec) delivered at 1 Hz. Action potentials were recorded continuously during 5 minute exposure to acetate followed by 5 minutes washout. Average traces constructed from 25 consecutive action potentials during control, acetate exposure (2 minutes) and washout (5 minutes) were analyzed. Action potential duration (APD90) was determined at 90% repolarization and referenced to the peak of the action potential.

Data analysis

All data were analyzed using ClampFit, IonWizard, ImageJ and Microsoft Excel software and (except where noted) results are presented as mean ± SEM (standard error of the mean). Statistical analysis was performed with built-in functions of Excel or with the Sigma XL software add-in. Statistical tests and p-values are denoted in the figure legend and text where appropriate.


Acute exposure to acetate transiently impairs cardiac contraction and increases diastolic sarcomere length

To test whether the short chain fatty acid, acetate, exerts negative inotropic effects, we continuously monitored average sarcomere length in isolated mouse cardiomyocytes acutely exposed to Tyrode solution containing 10 mM sodium acetate. Three major consequences of acetate exposure were observed. Figure 1 shows that acetate caused a transient decrease in active sarcomere shortening. At two minutes following acetate application, fractional shortening was markedly decreased from 5.6 ± 0.5 to 1.5 ± 0.2 (n = 12, p < 0.001, paired t-test). In the continued presence of acetate, contraction amplitude gradually recovered and returned to baseline after approximately 10 minutes. We also noted a marked increase in fractional sarcomere shortening when acetate was removed from the bath solution. In addition, exposure to acetate significantly increased the diastolic sarcomere length. We next examined the concentration dependence of the decrease in contraction observed at two minutes and diastolic sarcomere length following the exposure to acetate. Figure 2 shows that the negative inotropic effect of acetate is concentration dependent. Data were fit with a modified Hill equation with an IC50 = 5.6 mM and Hill coefficient of 1.4. There was no apparent concentration dependence for the effect on diastolic sarcomere length.

Figure 1

Acetate causes a transient decrease of fractional sarcomere shortening and an increase in diastolic sarcomere length in isolated mouse cardiac myocytes. (A) Representative recording of average sarcomere length assessed continuously throughout application and removal of normal Tyrode solution (NT) supplemented with 10 mM sodium acetate. Summary data from experiments as in A (n = 15), illustrating the effects of acetate on (B) fractional sarcomere shortening and (C) diastolic sarcomere length.

Figure 2

Concentration-dependence of acetate effect on fractional shortening and diastolic sarcomere length. (A) Single averaged contractions acquired in experiments as described in Figure 1 at different concentrations of sodium acetate. Contractions in normal Tyrode (Control, dotted line) and at 2 minutes following exposure to acetate solution (Acetate, solid line) are shown. 10 mM NaCl, instead of sodium acetate, was added to normal Tyrode to collect the zero acetate data. (B) Acetate concentration response curve for maximum contraction inhibition. Data were fit with a modified Hill equation (solid line): FS/FS0 = 1/(1 + ([Acetate]/IC50)h), where IC50 is the half-maximal inhibitory concentration of acetate (IC50 = 5.6 mM) and h is the Hill coefficient (h = 1.3). (C) There was no apparent acetate concentration dependence on diastolic sarcomere length.

Acetate exposure does not affect the action potential duration

We previously demonstrated that acute exposure to long chain fatty acids shortens the action potential duration principally by increasing outward voltage-dependent K+ currents encoded by Kv2.1 and Kv1.5, with no effect on IK1[2]. Considering that short-chain fatty acids might have similar effects on cell excitability, we examined the effect of acetate on the action potential duration (APD90) (Figure 3). In contrast to results with palmitate, APD90 (24.5 ± 3.2 msec in control) was unaffected by acetate (25.0 ± 3.5 msec, p >0.05, paired t-test), suggesting that a different molecular mechanism underlies the inotropic effects of acetate.

Figure 3

Acetate does not affect the action potential duration (APD 90 ). (A) Representative action potentials recorded before (Control, gray line) and 2 minutes following acetate exposure (Acetate, black line). Action potentials were recorded in whole cell current clamp mode and were evoked suprathreshold current injections. Records are averaged traces from 25 consecutive action potentials. (B) Summary APD90 data from all (n = 7) experiments as in A. Acetate exposure did not affect the APD90 (24.5 ± 3.2 msec in acetate vs. 25.0 ± 3.5 msec in control).

Acetate exposure stimulates mitochondrial Ca2+ uptake

It has been shown previously that acetate increases Ca2+ uptake in isolated liver and heart mitochondria [13]-[15]. In this light, we hypothesized that the acute application of acetate might lead to an increase in mitochondrial Ca2+ uptake, leaving less Ca2+ available to activate the myofilaments. To test this hypothesis, we first monitored mitochondrial Ca2+ during exposure to acetate using the fluorescent Ca2+ indicator, Rhod-2 AM (5 μM) in the presence of 200 μM MnCl2 to quench cytosolic fluorescence [17],[18]. Figure 4 shows normalized cell fluorescence during exposure to 10 mM acetate in the presence or absence of the mitochondrial Ca2+ uptake inhibitor, Ru-360 (n = 9 and 8 respectively). This concentration of Ru-360 was chosen as it has previously been shown to have no effect on transmembrane Ca2+ fluxes other than mitochondrial uptake [19],[20]. The results indicate that acetate causes a specific increase in Rhod-2 fluorescence consistent with the conclusion that acetate increases mitochondrial Ca2+ uptake.

Figure 4

Acetate stimulates mitochondrial Ca2+uptake. Summary of rhod-2-AM fluorescence recorded during exposure to 10 mM sodium acetate in the presence (n = 8) or absence (n = 10) of Ru-360 (10 μM). Background-subtracted fluorescence was normalized to mean fluorescence during the period prior to addition of 10 mM acetate (n =10) or control (no acetate, n = 9). Acetate solution was added at the arrow.

Inhibition of mitochondrial Ca2+ uptake attenuates the effects of acetate on fractional shortening and diastolic sarcomere length

If the acetate-dependent increase in mitochondrial Ca2+ is responsible for the reduction of myocyte fractional shortening, we reasoned that inhibiting mitochondrial Ca2+ uptake would reduce or abolish the effect of acetate on myocyte contraction. To test this hypothesis, we incubated cells for 30 minutes with 10 μM Ru-360, and then measured the effects of acetate on sarcomere shortening. Figure 5 shows that Ru-360 treatment significantly attenuated the effect of acetate on both diastolic sarcomere length and fractional sarcomere shortening. Interestingly, pretreatment with Ru-360 alone also had a marked effect on contractile function prior to acetate exposure. As shown in Figure 5B (inset), fractional sarcomere shortening immediately prior to acetate exposure (time zero) was 13.03 ± 1.17% in cells pretreated with Ru-360 compared with 5.83 ± 0.43% in control cells not exposed to Ru-360. Taken together, these data support the conclusion that acetate stimulates mitochondrial Ca2+ uptake, leading to reduced availability of Ca2+ for myofilament activation.

Figure 5

Inhibition of mitochondrial Ca2+uptake with Ru-360 inhibits the effects of acetate on cell contraction. (A) Representative recording of average sarcomere length assessed continuously throughout application and removal of normal Tyrode solution (NT) supplemented with 10 mM sodium acetate in cells pretreated with 10 μM Ru-360 for 30–60 minutes and maintained in Ru-360 throughout the acetate exposure. Summary data from experiments as in A (n = 11) illustrate that pretreatment with Ru-360 markedly suppresses the effect of acetate on both (B) fractional shortening and (C) diastolic sarcomere length.

Partial inhibition of SERCA inhibits recovery of systolic function during acetate application

The acetate-induced stimulation of mitochondrial Ca2+ uptake appears to be the seminal event leading to reduced inotropy. However, in the sustained presence of acetate, fractional shortening recovers to control levels by 10 minutes. This suggests that during the early phase of acetate exposure, cytosolic Ca2+ released from the SR bypasses the myofilaments and enters the mitochondria. We hypothesized that the recovery of contraction during the latter phase of acetate exposure reflects refilling of the SR to replace the Ca2+ lost to the mitochondria. Previous studies have utilized brief application of 1 μM thapsigargin to partially inhibit SERCA activity [21]. We therefore treated cells with 1 μM thapsigargin for 2–5 minutes prior to transfer to the bath for recording. No thapsigargin was added to the recording solutions. As expected, cell relaxation was markedly slowed by SERCA inhibition and therefore cells were stimulated at 0.5 Hz (instead of 1 Hz) for these experiments (Figure 6). Thapsigargin pretreatment markedly inhibited fractional shortening as expected (Figure 6B, inset), but exposure to acetate still resulted in a decrease in contraction amplitude and increase in diastolic sarcomere length similar to control, untreated cells. It should be noted, however, that the recovery of contraction typically observed during the latter phase of acetate application as well as the transient increase in contraction at washout were not observed in experiments where myocytes were briefly exposed to thapsigargin prior to acetate. This finding suggests that the recovery of contraction during acetate treatment reflects refilling of the sarcomplasmic reticulum with Ca2+.

Figure 6

Thapsigargin pretreatment specifically impairs the recovery of contraction during acetate exposure. (A) Representative recording of average sarcomere length assessed continuously throughout application and removal of normal Tyrode solution (NT) supplemented with 10 mM sodium acetate in cells pretreated with thapsigargin (1 μM) for 2–5 minutes. As expected, cell relaxation was markedly slowed so contractions were evoked at 0.5 Hz. (B & C) Summary data from experiments as in A (n = 9). Thapsigargin pretreatment had no effect on the acetate induced decrease in fractional shortening or increase in diastolic sarcomere length, but markedly blunted the recovery of contraction typically observed from 2–10 minutes during acetate application.


Acetate and cardiac function

There have been previous studies that have examined the effects of acetate on cardiovascular function and energetics in different contexts. Consistent with the results of the present study, acetate is reported to exhibit negative inotropic effects which appear to be transient [4],[5]. It should also be noted that acetate infusion can also cause an acute reduction of the blood pressure that is most likely dependent on the increase in AMP associated with the conversion of acetate to acetyl CoA and local release of the vasodilator adenosine [6], complicating the interpretation of experiments in vivo. Nevertheless, the data in the present study indicate that acetate exerts effects on cardiac contraction by directly modulating myocyte function, at least partially independent of energy metabolism.

A possible role for mitochondrial Ca2+ uptake in regulating contractile function

The present data provide evidence for a calcium-dependent mechanism linking acetate exposure with contractile function. Unlike the long chain fatty acid palmitate [2], the short chain fatty acid acetate caused no marked change in APD. Instead, we provide evidence that acetate caused a marked increased in mitochondrial Ca2+ accumulation. Moreover, the effect of acetate was markedly attenuated by pretreatment of myocytes with Ru-360, an inhibitor of mitochondrial Ca2+ uptake. Ru-360 is commonly used to inhibit mitochondrial Ca2+ uptake in a number of studies due to its ability to permeate cell membranes and it has been previously shown to have little if any effect on other transmembrane Ca2+ transport processes, including SR Ca2+ uptake and release, L-type Ca2+ channel and sodium calcium exchange function [19]. Our data is consistent with the conclusion that acetate uptake is coupled with an increase in mitochondrial Ca2+ and that this decreases, at least transiently, the amount of Ca2+ available for contraction of unloaded cardiomyocytes.

Interestingly, the effects of acetate on cell contraction were transient, with complete recovery of fractional shortening within 10 minutes of continuous exposure. This result could imply that as Ca2+ is sequestered in the mitochondria in the presence of acetate, additional Ca2+ enters the cell and refills the SR Ca2+ stores. We found that the acute decrease in contraction amplitude and increase in diastolic sarcomere length were unaffected by pretreatment with thapsigargin to attenuate SERCA activity. Interestingly, however, the recovery of depressed myocyte contractility during sustained acetate exposure and the abrupt increase in contraction amplitude due to acetate removal were no longer observed when cells were pretreated with thapsigargin. One possible explanation of this phenomenon is that inhibition of SR Ca2+ store replenishment prevents the restoration of fractional shortening.

Acetate effects on mitochondria

Mitochondrial uptake of acetate has been shown to be coupled with increases in Ca2+ uptake and swelling [13]. It was proposed that direct transport of phosphate or anions of weak acids like acetate can permeate the mitochondrial membrane generatings a driving force for Ca2+ uptake into the mitochondrial matrix. Similar observations demonstrate that acetate or phosphate increase the rate of mitochondrial Ca2+ uptake in a concentration dependent manner [14] and that acetate increases mitochondrial Ca2+ uptake in heart mitochondria [15]. The data in the present study do not delineate the molecular transporters mediating Ca2+ entry into the mitochondria. In addition to the mitochondrial Ca2+ uniporter [22], the mitochondrial ryanodine receptor (mRyr) [23], or Ca2+/H+ exchanger (Letm1) [24] could play a role in the acetate-induced increase in mitochondrial Ca2+. Nevertheless, here we present pharmacological evidence showing that acetate is apparently coupled with an increase in mitochondrial Ca2+ in isolated cardiac myocytes and it is plausible to assume that this decreases the amount of Ca2+ available for contraction.

In isolated mitochondria, acetate also caused osmotic swelling [13]. Given the tight interfibrillar packing of mitochondria in the heart [25],[26], acetate associated mitochondrial swelling might also be linked to the observed increase in diastolic sarcomere length. Interestingly, the effect of acetate on diastolic sarcomere length, unlike the effect on contraction, is sustained throughout acetate exposure and shows little concentration dependence. This observation is consistent with the conclusion that acetate causes the mitochondria to swell increasing the sarcomere spacing. While active cell shortening recovers as the SR refills with Ca2+, the mitochondria remain swollen and the increased diastolic sarcomere length is maintained. Given the structural constraints, it seems possible that swelling is physically limited possibly explaining the absence of a clear concentration dependence.

The observed delay from acetate application to initial effects on contraction is similar to the time course for conversion of acetate to acetyl CoA observed by Randle [10]. Acetate has been shown to decrease the phosphorylation potential [27] resulting in decreased free energy from ATP hydrolysis; since the demand likely remains constant, the cell must increase the rate of respiration to cover the difference. This might suggest that acetate oxidation increases mitochondrial respiration with concomitant increases in mitochondrial Ca2+. However, this is very unlikely since substrate availability governs only the pathways used to generate ATP, while workload or demand is the principal determinant of respiration [12],[28]. In unloaded myocytes paced at a constant frequency, it is expected that the workload is constant; therefore, it is unlikely that acetate-induced changes in respiration underlie the increase in mitochondrial Ca2+ uptake. Rather, we consider the possibility that mitochondrial uptake of the acetate anion is electrically balanced by the uptake of Ca2+ in line with the conclusion of others based on experiments with isolated mitochondria [13]-[15].

Short chain fatty acids like acetate and butyrate may also cause changes in intracellular pH with effects on contraction and SR Ca2+ content [29],[30]. The current data do not preclude a role for cytoplasm acidification in the effect of acetate on myocyte contraction. However, the observations that acetate increases mitochondrial Ca2+ and that pretreatment of cells with Ru-360 markedly attenuates the effects of acetate argues that an acute change in mitochondrial Ca2+ uptake, rather than cytoplasmic acidification, is the predominant mechanism underlying the effects of acetate on contraction. Moreover, it is tempting to predict that other anions of weak organic acids (e.g. lactate, butyrate, or pyruvate) may cause similar changes.

Mitochondrial Ca2+ uptake and cardiovascular disease

In the heart, mitochondrial Ca2+ uptake has been proposed as an important player in regulating cardiac energetics, reactive oxygen species generation and supply–demand matching [31],[32]; however, mitochondrial Ca2+ overload is also associated with the activation of cell death pathways [33]. Thus a balance in mitochondrial Ca2+ loading is required in order to achieve proper regulation of metabolism, but avoid overloading and cell death. In ischemia-reperfusion experiments, excessive Ca2+ uptake is associated with a poor outcome, and treatment with Ru-360 to inhibit mitochondrial Ca2+ uptake is beneficial [34]. Acetate in this setting would be predicted to have no effect or be detrimental, and this has been shown to be the case [3],[35]-[37]. Conversely, the failing heart has been shown to have reduced mitochondrial Ca2+ resulting from increases in cytosolic Na+ concentrations and increased mitochondrial sodium-calcium exchange activity and blocking mitochondrial Ca2+ export (i.e. enhancing mitochondrial Ca2+) is beneficial [38]. The data in the present study suggest that elevating circulating acetate might be an alternative strategy to accomplish this goal, although it should be noted that the study presented here was focused on the transient and not steady state consequences of acetate.


In summary, we have shown that acetate causes an acute but transient reduction in contractile function in isolated cardiac myocytes. Mechanistically, the transient negative inotropic effect appears to result from an acetate-dependent increase in mitochondrial Ca2+ uptake. This finding is consistent with the results of Lehninger and others using isolated liver and heart mitochondria, where it has been shown that acetate causes an increase in mitochondrial Ca2+ uptake and osmotic swelling [13]-[15]. Here we show that this effect appears to extend into intact, hydraulically unloaded cardiomyocytes, possibly suggesting a novel way to modulate mitochondrial Ca2+ homeostasis in the intact heart in vivo.


  1. 1.

    Flagg TP, Cazorla O, Remedi MS, Haim TE, Tones MA, Bahinski A, Numann RE, Kovacs A, Schaffer JE, Nichols CG, Nerbonne JM: Ca2 + −independent alterations in diastolic sarcomere length and relaxation kinetics in a mouse model of lipotoxic diabetic cardiomyopathy. Circ Res 2009,104(1):95-103. 10.1161/CIRCRESAHA.108.186809

  2. 2.

    Haim TE, Wang W, Flagg TP, Tones MA, Bahinski A, Numann RE, Nichols CG, Nerbonne JM: Palmitate attenuates myocardial contractility through augmentation of repolarizing Kv currents. J Mol Cell Cardiol 2010,48(2):395-405. 10.1016/j.yjmcc.2009.10.004

  3. 3.

    Martin BJ, Valdivia HH, Bunger R, Lasley RD, Mentzer RM Jr: Pyruvate augments calcium transients and cell shortening in rat ventricular myocytes. Am J Physiol 1998,274(1 Pt 2):H8-H17.

  4. 4.

    Kirkendol PL, Pearson JE, Bower JD, Holbert RD: Myocardial depressant effects of sodium acetate. Cardiovasc Res 1978,12(2):127-136. 10.1093/cvr/12.2.127

  5. 5.

    Jacob AD, Elkins N, Reiss OK, Chan L, Shapiro JI: Effects of acetate on energy metabolism and function in the isolated perfused rat heart. Kidney Int 1997,52(3):755-760. 10.1038/ki.1997.392

  6. 6.

    Liang CS, Lowenstein JM: Metabolic control of the circulation. Effects of acetate and pyruvate. J Clin Invest 1978,62(5):1029-1038. 10.1172/JCI109207

  7. 7.

    Ballard FJ: Supply and utilization of acetate in mammals. Am J Clin Nutr 1972,25(8):773-779.

  8. 8.

    Skutches CL, Holroyde CP, Myers RN, Paul P, Reichard GA: Plasma acetate turnover and oxidation. J Clin Invest 1979,64(3):708-713. 10.1172/JCI109513

  9. 9.

    Fujino T, Kondo J, Ishikawa M, Morikawa K, Yamamoto TT: Acetyl-CoA synthetase 2, a mitochondrial matrix enzyme involved in the oxidation of acetate. J Biol Chem 2001,276(14):11420-11426. 10.1074/jbc.M008782200

  10. 10.

    Randle PJ, England PJ, Denton RM: Control of the tricarboxylate cycle and its interactions with glycolysis during acetate utilization in rat heart. Biochem J 1970,117(4):677-695.

  11. 11.

    Williamson JR: Effects of insulin and starvation on the metabolism of acetate and pyruvate by the perfused rat heart. Biochem J 1964,93(1):97-106.

  12. 12.

    Taegtmeyer H, Hems R, Krebs HA: Utilization of energy-providing substrates in the isolated working rat heart. Biochem J 1980,186(3):701-711.

  13. 13.

    Lehninger AL: Role of phosphate and other proton-donating anions in respiration-coupled transport of Ca2+ by mitochondria. Proc Natl Acad Sci U S A 1974,71(4):1520-1524. 10.1073/pnas.71.4.1520

  14. 14.

    Reed KC, Bygrave FL: A kinetic study of mitochondrial calcium transport. Eur J Biochem 1975,55(3):497-504. 10.1111/j.1432-1033.1975.tb02187.x

  15. 15.

    Harris EJ: Anion/calcium ion ratios and proton production in some mitochondrial calcium ion uptakes. Biochem J 1978,176(3):983-991.

  16. 16.

    Flagg TP, Charpentier F, Manning-Fox J, Remedi MS, Enkvetchakul D, Lopatin A, Koster J, Nichols C: Remodeling of excitation-contraction coupling in transgenic mice expressing ATP-insensitive sarcolemmal K-ATP channels. Am J Physiol Heart Circ Physiol 2004,286(4):H1361-H1369. 10.1152/ajpheart.00676.2003

  17. 17.

    Pan X, Liu J, Nguyen T, Liu C, Sun J, Teng Y, Fergusson MM, Rovira II, Allen M, Springer DA, Aponte AM, Gucek M, Balaban RS, Murphy E, Finkel T: The physiological role of mitochondrial calcium revealed by mice lacking the mitochondrial calcium uniporter. Nat Cell Biol 2013,15(12):1464-1472. 10.1038/ncb2868

  18. 18.

    Miyata H, Silverman HS, Sollott SJ, Lakatta EG, Stern MD, Hansford RG: Measurement of mitochondrial free Ca2+ concentration in living single rat cardiac myocytes. Am J Physiol 1991,261(4 Pt 2):H1123-H1134.

  19. 19.

    Matlib MA, Zhou Z, Knight S, Ahmed S, Choi KM, Krause-Bauer J, Phillips R, Altschuld R, Katsube Y, Sperelakis N, Bers DM: Oxygen-bridged dinuclear ruthenium amine complex specifically inhibits Ca2+ uptake into mitochondria in vitroand in situ in single cardiac myocytes. J Biol Chem 1998,273(17):10223-10231. 10.1074/jbc.273.17.10223

  20. 20.

    Zhou Z, Bers D: Time course of action of antagonists of mitochondrial Ca uptake in intact ventricular myocytes. Pflugers Arch 2002,445(1):132-138. 10.1007/s00424-002-0909-7

  21. 21.

    Bode EF, Briston SJ, Overend CL, O’Neill SC, Trafford AW, Eisner DA: Changes of SERCA activity have only modest effects on sarcoplasmic reticulum Ca2+ content in rat ventricular myocytes. J Physiol 2011,589(19):4723-4729. 10.1113/jphysiol.2011.211052

  22. 22.

    Marchi S, Pinton P: The mitochondrial calcium uniporter complex: molecular components, structure and physiopathological implications. J Physiol 2014,592(Pt 5):829-839. 10.1113/jphysiol.2013.268235

  23. 23.

    Beutner G, Sharma VK, Giovannucci DR, Yule DI, Sheu SS: Identification of a ryanodine receptor in rat heart mitochondria. J Biol Chem 2001,276(24):21482-21488. 10.1074/jbc.M101486200

  24. 24.

    Jiang D, Zhao L, Clapham DE: Genome-Wide RNAi Screen Identifies Letm1 as a Mitochondrial Ca2+/H+ Antiporter. Science 2009,326(5949):144-147. 10.1126/science.1175145

  25. 25.

    Lukyanenko V, Chikando A, Lederer WJ: Mitochondria in cardiomyocyte Ca2+ signaling. Int J Biochem Cell Biol 2009,41(10):1957-1971. 10.1016/j.biocel.2009.03.011

  26. 26.

    Ong S-B, Hausenloy DJ: Mitochondrial morphology and cardiovascular disease. Cardiovasc Res 2010,88(1):16-29. 10.1093/cvr/cvq237

  27. 27.

    Kang YH, Mallet RT, Bunger R: Coronary autoregulation and purine release in normoxic heart at various cytoplasmic phosphorylation potentials: disparate effects of adenosine. Pflugers Arch 1992,421(2–3):188-199. 10.1007/BF00374826

  28. 28.

    Neely JR, Denton RM, England PJ, Randle PJ: The effects of increased heart work on the tricarboxylate cycle and its interactions with glycolysis in the perfused rat heart. Biochem J 1972,128(1):147-159.

  29. 29.

    Bountra C, Vaughan-Jones RD: Effect of intracellular and extracellular pH on contraction in isolated, mammalian cardiac muscle. J Physiol 1989, 418: 163-187. 10.1113/jphysiol.1989.sp017833

  30. 30.

    O’Neill SC, Eisner DA: pH-dependent and -independent effects inhibit Ca2 + −induced Ca2+ release during metabolic blockade in rat ventricular myocytes. J Physiol 2003,550(2):413-418. 10.1113/jphysiol.2003.042846

  31. 31.

    Balaban RS: Cardiac energy metabolism homeostasis: role of cytosolic calcium. J Mol Cell Cardiol 2002,34(10):1259-1271. 10.1006/jmcc.2002.2082

  32. 32.

    Liu T, O’Rourke B: Regulation of mitochondrial Ca2+ and its effects on energetics and redox balance in normal and failing heart. J Bioenerg Biomembr 2009,41(2):127-132. 10.1007/s10863-009-9216-8

  33. 33.

    Garcia-Dorado D, Ruiz-Meana M, Inserte J, Rodriguez-Sinovas A, Piper HM: Calcium-mediated cell death during myocardial reperfusion. Cardiovasc Res 2012,94(2):168-180. 10.1093/cvr/cvs116

  34. 34.

    Garcia-Rivas Gde J, Carvajal K, Correa F, Zazueta C: Ru360, a specific mitochondrial calcium uptake inhibitor, improves cardiac post-ischaemic functional recovery in rats in vivo. Br J Pharmacol 2006,149(7):829-837. 10.1038/sj.bjp.0706932

  35. 35.

    Mallet RT, Sun J, Knott EM, Sharma AB, Olivencia-Yurvati AH: Metabolic cardioprotection by pyruvate: recent progress. Exp Biol Med (Maywood) 2005,230(7):435-443.

  36. 36.

    Bunger R, Mallet RT: Mitochondrial pyruvate transport in working guinea-pig heart. Work-related vs carrier-mediated control of pyruvate oxidation. Biochim Biophys Acta 1993,1151(2):223-236. 10.1016/0005-2736(93)90107-B

  37. 37.

    Bunger R, Mallet RT, Hartman DA: Pyruvate-enhanced phosphorylation potential and inotropism in normoxic and postischemic isolated working heart. Near-complete prevention of reperfusion contractile failure. Eur J Biochem 1989,180(1):221-233. 10.1111/j.1432-1033.1989.tb14637.x

  38. 38.

    Liu T, O’Rourke B: Enhancing mitochondrial Ca2+ uptake in myocytes from failing hearts restores energy supply and demand matching. Circ Res 2008,103(3):279-288. 10.1161/CIRCRESAHA.108.175919

Download references


This work was supported by funding from the Henry M. Jackson Foundation (to TPF) and the Department of Defense (R0702O to TPF).


The views expressed are those of the authors and do not reflect the official policy or position of the Uniformed Services University of the Health Sciences, the Department of the Defense, or the United States governmen.

Author information

Correspondence to Thomas P Flagg.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

JS performed the cell shortening experiments and analyzed data. AN participated in the design of the study and manuscript revision. RC performed mitochondrial Ca2+ uptake measurements and analyzed data. RB participated in the design of the study, data interpretation, and manuscript revision. TF performed electrophysiology experiments, cell shortening experiments, analyzed data, and drafted the manuscript. All authors read and approved the final manuscript.

Authors’ original submitted files for images

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Schooley, J.F., Namboodiri, A.M., Cox, R.T. et al. Acetate transiently inhibits myocardial contraction by increasing mitochondrial calcium uptake. BMC Physiol 14, 12 (2014) doi:10.1186/s12899-014-0012-2

Download citation


  • Short Chain Fatty Acid
  • Ventricular Myocytes
  • Action Potential Duration
  • Thapsigargin
  • Negative Inotropic Effect